170 related articles for article (PubMed ID: 18592360)
1. Palifermin mediates immunoregulatory effects in addition to its cytoprotective effects in mice with acute graft-versus-host disease.
Ellison CA; Makar BM; Wiseman JM; Gheorghiu I; Taniguchi M; Gartner JG
J Clin Immunol; 2008 Sep; 28(5):600-15. PubMed ID: 18592360
[TBL] [Abstract][Full Text] [Related]
2. Immunomodulatory effects of palifermin (recombinant human keratinocyte growth factor) in an SLE-like model of chronic graft-versus-host disease.
Ellison CA; Lissitsyn YV; Gheorghiu I; Gartner JG
Scand J Immunol; 2012 Jan; 75(1):69-76. PubMed ID: 21916922
[TBL] [Abstract][Full Text] [Related]
3. Role of thymic stromal lymphopoietin (TSLP) in palifermin-mediated immune modulation and protection from acute murine graft-versus-host disease.
Ellison CA; Lissitsyn YV; Packiasamy JA; Leonard WJ; Gartner JG
J Clin Immunol; 2011 Jun; 31(3):406-13. PubMed ID: 21161346
[TBL] [Abstract][Full Text] [Related]
4. Effect of palifermin in a murine model of graft-versus-host disease (GVHD) associated with Th2 cytokine production, autoantibody production, and glomerulonephritis.
Ellison CA; Gibson IW; Hayglass KT; Gartner JG
J Clin Immunol; 2006 Sep; 26(5):485-94. PubMed ID: 16952010
[TBL] [Abstract][Full Text] [Related]
5. Graft-versus-host disease in recipients of grafts from natural killer T cell-deficient (Jalpha281(-/-)) donors.
Ellison CA; Taniguchi M; Fischer JM; Hayglass KT; Gartner JG
Immunology; 2006 Nov; 119(3):338-47. PubMed ID: 16879624
[TBL] [Abstract][Full Text] [Related]
6. Effect of recombinant human keratinocyte growth factor (rHuKGF) on the immunopathogenesis of intestinal graft-vs.-host disease induced without a preconditioning regimen.
Ellison CA; Natuik SA; Fischer JM; McIntosh AR; Scully SA; Bow EJ; Danilenko DM; Hayglass KT; Gartner JG
J Clin Immunol; 2004 Mar; 24(2):197-211. PubMed ID: 15024187
[TBL] [Abstract][Full Text] [Related]
7. Depletion of natural killer cells from the graft reduces interferon-gamma levels and lipopolysaccharide-induced tumor necrosis factor-alpha release in F1 hybrid mice with acute graft-versus-host disease.
Ellison CA; HayGlass KT; Fischer JM; Rector ES; MacDonald GC; Gartner JG
Transplantation; 1998 Aug; 66(3):284-94. PubMed ID: 9721794
[TBL] [Abstract][Full Text] [Related]
8. Long-term follow-up of a phase I/II randomized, placebo-controlled trial of palifermin to prevent graft-versus-host disease (GVHD) after related donor allogeneic hematopoietic cell transplantation (HCT).
Levine JE; Blazar BR; DeFor T; Ferrara JLM; Weisdorf DJ
Biol Blood Marrow Transplant; 2008 Sep; 14(9):1017-1021. PubMed ID: 18721764
[TBL] [Abstract][Full Text] [Related]
9. Host conditioning with total lymphoid irradiation and antithymocyte globulin prevents graft-versus-host disease: the role of CD1-reactive natural killer T cells.
Lan F; Zeng D; Higuchi M; Higgins JP; Strober S
Biol Blood Marrow Transplant; 2003 Jun; 9(6):355-63. PubMed ID: 12813443
[TBL] [Abstract][Full Text] [Related]
10. Roquinimex-mediated protection effect on the development of chronic graft-versus-host disease in mice is associated with induction of Th1 cytokine production and inhibition of proinflammatory cytokine production.
Xiao ZY; Zhou WX; Zhang YX; Cheng JP; He JF; Yang RF; Yun LH
Life Sci; 2007 Oct; 81(19-20):1403-10. PubMed ID: 17950363
[TBL] [Abstract][Full Text] [Related]
11. Kinetics of Th1 and Th2 cytokine production during the early course of acute and chronic murine graft-versus-host disease. Regulatory role of donor CD8+ T cells.
Rus V; Svetic A; Nguyen P; Gause WC; Via CS
J Immunol; 1995 Sep; 155(5):2396-406. PubMed ID: 7650373
[TBL] [Abstract][Full Text] [Related]
12. Neutralizing IL-12 during induction of murine acute graft-versus-host disease polarizes the cytokine profile toward a Th2-type alloimmune response and confers long term protection from disease.
Williamson E; Garside P; Bradley JA; More IA; Mowat AM
J Immunol; 1997 Aug; 159(3):1208-15. PubMed ID: 9233615
[TBL] [Abstract][Full Text] [Related]
13. Differential effect of CTLA4Ig on murine graft-versus-host disease (GVHD) development: CTLA4Ig prevents both acute and chronic GVHD development but reverses only chronic GVHD.
Via CS; Rus V; Nguyen P; Linsley P; Gause WC
J Immunol; 1996 Nov; 157(9):4258-67. PubMed ID: 8892665
[TBL] [Abstract][Full Text] [Related]
14. Th1 and Th2 mediate acute graft-versus-host disease, each with distinct end-organ targets.
Nikolic B; Lee S; Bronson RT; Grusby MJ; Sykes M
J Clin Invest; 2000 May; 105(9):1289-98. PubMed ID: 10792004
[TBL] [Abstract][Full Text] [Related]
15. Keratinocyte growth factor preserves normal thymopoiesis and thymic microenvironment during experimental graft-versus-host disease.
Rossi S; Blazar BR; Farrell CL; Danilenko DM; Lacey DL; Weinberg KI; Krenger W; Holländer GA
Blood; 2002 Jul; 100(2):682-91. PubMed ID: 12091365
[TBL] [Abstract][Full Text] [Related]
16. Keratinocyte growth factor facilitates alloengraftment and ameliorates graft-versus-host disease in mice by a mechanism independent of repair of conditioning-induced tissue injury.
Panoskaltsis-Mortari A; Taylor PA; Rubin JS; Uren A; Welniak LA; Murphy WJ; Farrell CL; Lacey DL; Blazar BR
Blood; 2000 Dec; 96(13):4350-6. PubMed ID: 11110712
[TBL] [Abstract][Full Text] [Related]
17. Donor CD4-enriched cells of Th2 cytokine phenotype regulate graft-versus-host disease without impairing allogeneic engraftment in sublethally irradiated mice.
Fowler DH; Kurasawa K; Smith R; Eckhaus MA; Gress RE
Blood; 1994 Nov; 84(10):3540-9. PubMed ID: 7949109
[TBL] [Abstract][Full Text] [Related]
18. Phase 1/2 randomized, placebo-control trial of palifermin to prevent graft-versus-host disease (GVHD) after allogeneic hematopoietic stem cell transplantation (HSCT).
Blazar BR; Weisdorf DJ; Defor T; Goldman A; Braun T; Silver S; Ferrara JL
Blood; 2006 Nov; 108(9):3216-22. PubMed ID: 16835378
[TBL] [Abstract][Full Text] [Related]
19. Pretreatment of donor mice with granulocyte colony-stimulating factor polarizes donor T lymphocytes toward type-2 cytokine production and reduces severity of experimental graft-versus-host disease.
Pan L; Delmonte J; Jalonen CK; Ferrara JL
Blood; 1995 Dec; 86(12):4422-9. PubMed ID: 8541530
[TBL] [Abstract][Full Text] [Related]
20. Treatment of donor mice with an alpha beta T-cell receptor monoclonal antibody induces prolonged T-cell nonresponsiveness and effectively prevents lethal graft-versus-host disease in murine recipients of major histocompatibility complex (MHC)-matched and MHC-mismatched donor marrow grafts.
Drobyski WR; Majewski D
Blood; 1996 Jun; 87(12):5355-69. PubMed ID: 8652851
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
